

Provincial and Municipal Support Policies of Biopharmacy

1. Medicine and health

Quality and Efficacy Consistency Evaluation of Generic Drugs		
Item	Scope of support	Subsidy and reward amount
Subsidy	For enterprises carrying out a consistency evaluation	A subsidy of 500,000 yuan will be granted for each variety.
Reward	For drugs that have passed the national consistency evaluation	A one-time reward of 500,000 yuan will be granted for each variety. For the variety first passing the domestic consistency evaluation, a one-time reward of 1 million yuan will be given.
	For drugs passed the consistency evaluation	A reward will be granted at 2% of the annual sales revenue of each variety for two consecutive years following the year when the drugs passed the consistency evaluation, with the cumulative total amount not exceeding 2 million yuan.
	For drugs that have passed the national consistency evaluation and whose APIs are independently produced by local enterprises in Hainan and have approval numbers.	The cap on the cumulative total reward is increased to 3 million yuan.

2. Pharmaceuticals

Reward	Eligibility Requirements	Reward Amount
Encouraging pharmaceutical enterprises to enhance and expand	For Haikou-based pharmaceutical enterprises that are included for the first time in the “Annual List of China’s Top 100 Pharmaceutical Enterprises” published by the Ministry of Industry and Information Technology	A one-time reward of 2 million yuan will be given, and for each subsequent rise in the previous highest ranking in the following year, a reward of 100,000 yuan will be granted.
Encouraging pharmaceutical enterprises to increase product	For pharmaceutical enterprises whose sales revenue of a single variety reached 100 million yuan (inclusive) to 300 million yuan (exclusive) in a year	A reward of 300,000 yuan will be granted

varieties

For pharmaceutical enterprises whose sales revenue of a single variety reached 300 million yuan (inclusive) to 500 million yuan (exclusive) in a year	A reward of 1 million yuan will be granted
For pharmaceutical enterprises whose sales revenue of a single variety reached 500 million yuan (inclusive) to 700 million yuan (exclusive) in a year	A reward of 2 million yuan will be granted
For pharmaceutical enterprises whose sales revenue of a single variety reached 700 million yuan (inclusive) to 1 billion yuan (exclusive) in a year	A reward of 4 million yuan will be granted
For pharmaceutical enterprises whose sales revenue of a single variety reached 1 billion yuan (inclusive) in a year	A reward of 6 million yuan will be granted
For pharmaceutical distribution enterprises whose sales revenue of a single variety reached 100 million yuan (inclusive) to 300 million yuan (exclusive) in a year	A reward of 20,000 yuan will be granted
For pharmaceutical distribution enterprises whose sales revenue of a single variety reached 300 million yuan (inclusive) to 500 million yuan (exclusive) in a year	A reward of 80,000 yuan will be granted
For pharmaceutical distribution enterprises whose sales revenue of a single variety reached 500 million yuan (inclusive) 1 to 700 million yuan (exclusive) in a year	A reward of 200,000 yuan will be granted
For pharmaceutical distribution enterprises whose sales revenue of a single variety reached 700 million yuan (inclusive) to 1 billion yuan (exclusive) in a year	A reward of 300,000 yuan will be granted
For pharmaceutical enterprises whose sales revenue of a single variety reached	A reward of 500,000 yuan will be granted

	1 billion yuan (inclusive) in a year	
	For pharmaceuticals imported from Hainan	The reward will be increased by 25%; pharmaceuticals not imported from Hainan will be deemed as domestic pharmaceuticals and the reward will be calculated accordingly
	Where the sales revenue of pharmaceuticals imported from Hainan is less than 100 million yuan, but the sales revenue of such pharmaceuticals and domestic ones reaches 100 million yuan	A reward will be given according to the standard of domestic pharmaceuticals
	Where the sales revenue of pharmaceuticals imported from Hainan reaches 100 million yuan	A reward will be given according to the standard for imported pharmaceuticals
Encouraging pharmaceutical companies to buy and introduce manufacturing licenses from regions outside Haikou, manufacture pharmaceuticals in Haikou, and realize contract manufacturing based on the marketing authorization holder and medical device registrant systems	For pharmaceutical enterprises to buy and introduce manufacturing licenses from regions outside Haikou and manufacture pharmaceuticals in Haikou	A reward of 1 million yuan will be given to each batch of the first year, and in subsequent manufacturing years, a reward will be granted at 2% of the annual sales revenue every year.
	For pharmaceutical enterprises which conduct contract manufacturing for MAHs (or medical device registrants) located outside Hainan or non-affiliated MAHs (or medical device registrants) in Haikou and take manufacturing and processing charges from such MAHs (or medical device registrants) based on the MAH and medical device registrant systems,	A reward will be given at 20% of the contract processing fees actually charged for three consecutive years from the year when they are approved as designated manufacturers of such MAHs (or medical device registrants), and a maximum of 15 million yuan will be rewarded to each variety, and each enterprise will receive a maximum of 30 million yuan in rewards each year.
Encouraging the construction of basic application platforms in the pharmaceutical	For pharmaceutical enterprises which accelerate the cultivation and introduction of industry-leading contract research organizations (CRO), contract manufacturing	Based on the invoices, payment vouchers and contracts within the retrospective period, a one-time subsidy will be granted at 20% of the total fixed asset

industry	<p>organizations (CMO), contract development and manufacturing organizations (CDMO) and other basic application platforms, with the total fixed assets investment (excluding land payment) in a single project exceeding 100 million yuan</p> <p>Enterprises enjoying this policy shall no longer enjoy the preferential policies related to “R&D Support for New Industrial Enterprises” and “Implementation of Transformation and Upgrading Strategy”.</p>	<p>investment (excluding land payments) upon the completion and commissioning of the project, with the maximum reward amount not exceeding 50 million yuan.</p>
Encouraging new drug development and independent innovation	<p>For pharmaceuticals manufactured in Haikou by pharmaceutical enterprises newly obtaining national drug registration approvals and manufacturing authorizations</p>	<p>A one-time subsidy will be granted.</p> <p>Subsidies for pharmaceutical chemicals:</p> <p>A subsidy of 10 million yuan will be granted for Class 1 pharmaceutical chemicals;</p> <p>A subsidy of 8 million yuan will be granted for Class 2.1 pharmaceutical chemicals;</p> <p>A subsidy of 7 million yuan will be granted for Class 2.2 pharmaceutical chemicals;</p> <p>A subsidy of 6 million yuan will be granted for Class 2.3 pharmaceutical chemicals;</p> <p>A subsidy of 5 million yuan will be granted for Class 2.4 pharmaceutical chemicals;</p> <p>A subsidy of 2 million yuan will be granted for Class 3 pharmaceutical chemicals;</p> <p>A subsidy of 1.5 million yuan will be granted for Class 4 pharmaceutical chemicals;</p> <p>A subsidy of 1 million yuan will be granted for Class 5 pharmaceutical chemicals.</p> <p>Subsidies for traditional Chinese medicines:</p> <p>A subsidy of 10 million yuan will be granted for Class 1 traditional Chinese medicines;</p>

		<p>A subsidy of 5 million yuan will be granted for Class 2 traditional Chinese medicines;</p> <p>A subsidy of 2 million yuan will be granted for Class 3 traditional Chinese medicines;</p> <p>A subsidy of 500,000 yuan will be granted for other traditional Chinese medicines.</p> <p>Subsidies for biological products</p> <p>A subsidy of 10 million yuan will be granted for Class 1 biological products;</p> <p>A subsidy of 5 million yuan will be granted for Class 2 biological products;</p> <p>A subsidy of 2.5 million yuan will be granted for Class 3 biological products:</p> <p>A subsidy of 1 million yuan will be granted for Class 4 and Class 5 biological products;</p> <p>A subsidy of 500,000 yuan will be granted for other biological products.</p>
	For enterprises obtaining the registration approvals for Class 2 and Class 3 medical devices (excluding Class 2 diagnostic reagents and equipment parts) and manufacturing such medical devices in Haikou	A reward of 200,000 yuan and 2 million yuan will be given in the year, respectively. If the sales revenues of a variety reach 20 million yuan and 50 million yuan, a one-time reward of 500,000 yuan and 3 million yuan will be given, respectively.
	For the first high-end medical equipment recognized by authorities at a provincial or higher level in Hainan	A subsidy will be granted at 2% of the annual sales revenue of the product within 3 years since the recognition day, and each enterprise will receive a maximum cumulative subsidy of 10 million yuan for each single product every year.
	The clinical research expenses of pharmaceutical enterprises will be	A subsidy will be granted at 5% of the previous year's actual

	subsidized. Where enterprises promise that the products involved in clinical research will be produced in Haikou after the manufacturing authorization is obtained	payment amount according to the payment schedule of clinical research expenses, and each enterprise will receive a maximum of 3 million yuan in subsidies for each drug specification.
Encouraging pharmaceutical enterprises to export products	For pharmaceutical enterprises with an annual export value of USD 1 million, USD 2 million, USD 5 million and USD 10 million respectively	An international market development reward of 100,000 yuan, 200,000 yuan, 500,000 yuan and 1 million yuan will be given respectively
	For pharmaceutical enterprises with an export amount of over USD 10 million	A reward of 500,000 yuan will be given on the basis of the 1 million yuan reward amount for every increase of USD 10 million in export amount, and each enterprise will receive a maximum of 5.5 million yuan in this reward.
Encouraging pharmaceutical enterprises to pass international certification	For pharmaceutical enterprises that have passed the certification by EDQM and FDA	A one-time reward of 1 million yuan will be granted for each time the enterprises pass such certification and realize practical export
	For pharmaceutical enterprises that have passed the certification by other countries	A one-time reward of 500,000 yuan will be granted for each time the enterprises pass such certification and realize practical export
Encouraging pharmaceutical enterprises to conduct international registration	For pharmaceutical enterprises whose products have obtained international registration approvals and been manufactured in Haikou,	a one-time subsidy will be granted at 100% of the registration fees incurred in obtaining the approvals for each international registration approval obtained for a variety, and the subsidy will not exceed 200,000 yuan at maximum. If practical export is realized, an additional one-time subsidy of 300,000 yuan will be granted.
	If an enterprise obtains multiple registration approvals for different specifications of a variety in a	A reward will be given for each registration approval obtained

	country	
	For pharmaceutical enterprises that have completed international registration and realized practical sales before the issuance and implementation of these regulations, rewards will be given as above, and no reward will be given for the re-registration of any international registration approval obtained.	